Results for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the quarter ended

Results for announcement to the market

The attached Form 10-Q Quarterly Report for the quarter ended June 30, 2025 has been filed

with the U.S. Securities and Exchange Commission. It includes the condensed consolidated financial statements which have been prepared in accordance with generally accepted accounting principles in the United States of America ("US GAAP") and are

denominated in U.S. dollars.

The following supplementary information is provided in connection with the Form 10-Q for the purposes of compliance with ASX Listing Rule 4.2A.3 in relation to half

year reports and 4.7C in relation to quarterly activity reports. This information should be read in conjunction with the Form 10-Q and is provided to satisfy the Company's ongoing disclosure obligations under the ASX Listing Rules.

The Company's results for announcement to the market are as follows:

No dividend has been proposed or declared for the reporting period.

Details of business activities during the quarter:

Refer to the Form 10-Q and the "Anteris Announces Results for the Second Quarter of 2025" announcement lodged with the ASX on August 12, 2025 AEST.

On December 12, 2024, our registration statement on Form S-1 relating to our initial public offering became effective pursuant to which we issued and sold 14,878,481

shares of Common Stock at a public offering price of US$6.00 per share.

We received net proceeds of US$80.0 million, after deducting the underwriting discounts, commissions and offering expenses and giving effect to the exercise of the

underwriters' option to purchase additional shares. The use of proceeds from our initial public offering, as of June 30, 2025, was as follows:

Aggregate amount of payments to related parties and their associates:

During the second quarter of 2025, the aggregate amount of payments to related parties and their associates (which includes director fees, Company secretarial fees,

CEO, President and CFO remuneration) was US$640 thousand. These payments were included in cash flows from operating activities.

There were no payments to related parties or their associates included in cash flows from investing activities.

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge

medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative

solutions to structural heart disease patients.

Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and

cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first

biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris' patented

anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the

DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts, including the objectives of and

plans for Anteris' studies and trials, the timing of the PARADIGM Trial, the goals of the expansion of the global manufacturing capacity and the sourcing of ADAPT tissue for the DurAVR THV in the future. Forward-looking

statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will

continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those

described under "Risk Factors" in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on

forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information: